Clinical trial NCT03024281: Surveillance of Azole Resistance in Aspergillus Isolates in Taiwan
Official title: Surveillance of Azole Resistance in Aspergillus
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infection; Aspergillus
Keywords: Aspergillus
Antifungal susceptibility
Azole resistance
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: National Health Research Institutes, Taiwan
First posted: 2017-01-18
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 10 hospitals located in different geographic location of Taiwan will be invited to participate this project. These hospitals are selected based on three criteria: better quality of routine microbiology laboratory (not reference laboratory), one or more physicians or microbiologists who are interested in medical mycology, and geographic location of the hospitals.

Brief summary: Primary objectives:

1. To investigate the prevalence of azole resistance in Aspergillus clinical isolates collected in participating hospitals in Taiwan
2. To investigate the prevalence of azole resistance in Aspergillus environmental isolates in Taiwan
3. To characterize the molecular mechanisms of azole resistance in Aspergillus isolates in Taiwan
4. To investigate the clonality of Aspergillus clinical and environmental isolates in Taiwan
5. To describe the genetic relationships between local resistant strains with global strains

Secondary objective:

1. To describe the clinical characteristics and treatment outcome of patients with proven or probable invasive aspergillosis
2. To evaluate the clinical impact of azole resistance in patients with proven or probable invasive aspergillosis in a case-control study

Detailed description: Cumulative evidence described the emergence and geographical expansion of azole-resistant Aspergillus fumigatus associated with azole treatment failure. Multiple amino acid substitutions in the cyp51A gene have been described to be associated with azole resistance that emerges during azole treatment, while a resistance mechanism, TR34/L98H mutation in cyp51A, has been linked to the agricultural use of azole fungicides in Europe, which have also been widely used in Taiwan for years. The current prevalence of azole-resistant Aspergillus isolates and mechanisms of azole resistance in Taiwan is not clear. Considering the potential of geographic migration of resistant isolates from neighboring countries and the possibility of emergence of locally revolved resistant strains, this 2-year multi-center project aims to investigate the prevalence rate of azole resistance in Aspergillus clinical and environmental isolates, to determine the molecular mechanisms of azole resistance, and to describe the clinical characteristics and treatment outcome of Aspergillus diseases in Taiwan. Clinical and environmental Aspergillus isolates will be collected and examined, and clinical data from patients with Aspergillus diseases or colonization will be retrieved and analyzed. Through this study the investigators anticipate increase in awareness of prevalence and impact of azole resistance in patient safety in participating hospitals. In addition, the investigators may update Taiwan treatment guideline for aspergillosis on the basis of these evidence and knowledge.

Eligibility criteria: For primary objectives

Inclusion Criteria:

* Patients with one or more clinical specimens culture positive of Aspergillus

Exclusion Criteria:

* Is not a human pathogen of Aspergillus
* no clinical data available

For secondary objectives (a case-control study in a 1:4 ratio)

Inclusion Criteria:

* patients with proven or probable invasive aspergillosis

Case patients: patients infected by azole-resistant isolates Control patients: patients infected by azole-susceptible isolates

Primary outcomes:
measure: Treatment success
timeFrame: 6 weeks after diagnosis of proven or probable invasive aspergillosis
Secondary outcomes:
measure: All-cause mortality
timeFrame: 6 weeks after diagnosis of proven or probable invasive aspergillosis
measure: All-cause mortality
timeFrame: 12 weeks after diagnosis of proven or probable invasive aspergillosis
measure: Breakthrough mold infections
timeFrame: 6 weeks after diagnosis of proven or probable invasive aspergillosis
measure: Breakthrough invasive fungal diseases
timeFrame: 12 weeks after diagnosis of proven or probable invasive aspergillosis
measure: Treatment success
timeFrame: 12 weeks after diagnosis of proven or probable invasive aspergillosis
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: WHO and ICMJE
name: WHO, ICMJE WHO and ICMJE
role: STUDY_DIRECTOR
References: